Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease
Standard
Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease. / Breidthardt, Tobias; Jaeger, Cedric; Christ, Andreas; Klima, Theresia; Mosimann, Tamina; Twerenbold, Raphael; Boeddinghaus, Jasper; Nestelberger, Thomas; Badertscher, Patrick; Struck, Joachim; Bergmann, Andreas; Hartmann, Oliver; Kalbermatter, Stefan; Marenzi, Giancarlo; Mueller, Christian.
in: EUR J CLIN INVEST, Jahrgang 48, Nr. 10, 10.2018, S. e12999.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease
AU - Breidthardt, Tobias
AU - Jaeger, Cedric
AU - Christ, Andreas
AU - Klima, Theresia
AU - Mosimann, Tamina
AU - Twerenbold, Raphael
AU - Boeddinghaus, Jasper
AU - Nestelberger, Thomas
AU - Badertscher, Patrick
AU - Struck, Joachim
AU - Bergmann, Andreas
AU - Hartmann, Oliver
AU - Kalbermatter, Stefan
AU - Marenzi, Giancarlo
AU - Mueller, Christian
N1 - © 2018 Stichting European Society for Clinical Investigation Journal Foundation.
PY - 2018/10
Y1 - 2018/10
N2 - BACKGROUND: The early detection of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) is an unmet clinical need. Proenkephalin (PENK) might improve the early detection of AKI.METHODS: One hundred and eleven hospitalized CKD patients undergoing radiographic contrast procedures were enrolled. PENK was measured in a blinded fashion at baseline (before contrast media administration) and on day 1 (after contrast media administration). The potential of PENK levels to predict contrast-induced AKI was the primary endpoint.RESULTS: Baseline creatinine and baseline PENK were similar in AKI and no-AKI patients. In AKI patients, day 1 PENK (198 pmol/L vs 121 pmol/L, P < 0.01) was significantly higher compared to no-AKI patients. The area under the curve (AUC) for the prediction of AKI by day 1 PENK was 0.79, 95% CI: 0.70-0.87, similar to serum creatinine: 0.78, 95% CI: 0.61-0.95. Delta PENK was significantly higher in AKI compared to no-AKI patients (53 pmol/L vs 1 pmol/L, P < 0.01). The AUC for the prediction of AKI by delta PENK was high (0.92, 95%CI 0.82-1.00) and remained high for creatinine-blind AKI (0.94, 95% CI: 0.87-0.97).CONCLUSION: Delta PENK levels improve the early detection of contrast-induced AKI in CKD patients over serial creatinine sampling. Delta PENK accelerates the detection of creatinine-blind AKI by 24 hours.
AB - BACKGROUND: The early detection of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) is an unmet clinical need. Proenkephalin (PENK) might improve the early detection of AKI.METHODS: One hundred and eleven hospitalized CKD patients undergoing radiographic contrast procedures were enrolled. PENK was measured in a blinded fashion at baseline (before contrast media administration) and on day 1 (after contrast media administration). The potential of PENK levels to predict contrast-induced AKI was the primary endpoint.RESULTS: Baseline creatinine and baseline PENK were similar in AKI and no-AKI patients. In AKI patients, day 1 PENK (198 pmol/L vs 121 pmol/L, P < 0.01) was significantly higher compared to no-AKI patients. The area under the curve (AUC) for the prediction of AKI by day 1 PENK was 0.79, 95% CI: 0.70-0.87, similar to serum creatinine: 0.78, 95% CI: 0.61-0.95. Delta PENK was significantly higher in AKI compared to no-AKI patients (53 pmol/L vs 1 pmol/L, P < 0.01). The AUC for the prediction of AKI by delta PENK was high (0.92, 95%CI 0.82-1.00) and remained high for creatinine-blind AKI (0.94, 95% CI: 0.87-0.97).CONCLUSION: Delta PENK levels improve the early detection of contrast-induced AKI in CKD patients over serial creatinine sampling. Delta PENK accelerates the detection of creatinine-blind AKI by 24 hours.
KW - Acute Kidney Injury/chemically induced
KW - Aged
KW - Aged, 80 and over
KW - Area Under Curve
KW - Biomarkers/metabolism
KW - Contrast Media/adverse effects
KW - Creatinine/metabolism
KW - Early Diagnosis
KW - Enkephalins/metabolism
KW - Female
KW - Hospitalization
KW - Humans
KW - Isotonic Solutions/administration & dosage
KW - Male
KW - Prospective Studies
KW - Protein Precursors/metabolism
KW - Renal Insufficiency, Chronic/complications
KW - Sodium Bicarbonate/administration & dosage
KW - Sodium Chloride/administration & dosage
U2 - 10.1111/eci.12999
DO - 10.1111/eci.12999
M3 - SCORING: Journal article
C2 - 30009473
VL - 48
SP - e12999
JO - EUR J CLIN INVEST
JF - EUR J CLIN INVEST
SN - 0014-2972
IS - 10
ER -